BiotechTube

mRNA-1010

Phase 1Completed
0 views this week 0 watching
0
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SARS-CoV-2, Influenza, RSV

Conditions

SARS-CoV-2, Influenza, RSV

Trial Timeline

Oct 14, 2022 → Feb 28, 2024

NCT ID
NCT05585632

About mRNA-1010

mRNA-1010 is a phase 1 stage product being developed by Moderna for SARS-CoV-2, Influenza, RSV. The current trial status is completed. This product is registered under clinical trial identifier NCT05585632. Target conditions include SARS-CoV-2, Influenza, RSV.

What happened to similar drugs?

4 of 20 similar drugs in SARS-CoV-2, Influenza, RSV were approved

Approved (4) Terminated (1) Active (16)
✅mRNA-1273 Variant-containing FormulationModernaApproved
✅mRNA-1273ModernaApproved
✅AZD1222AstraZenecaApproved
✅BNT162b2PfizerApproved
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1083ModernaPhase 3

Clinical Trials (8)

NCT IDPhaseStatus
NCT06602024Phase 3Completed
NCT05868382Phase 2Completed
NCT05827978Phase 3Completed
NCT05606965Phase 2Completed
NCT05585632Phase 1Completed
NCT05566639Phase 3Completed
NCT05415462Phase 3Completed
NCT04956575Phase 2Completed

Competing Products

20 competing products in SARS-CoV-2, Influenza, RSV

See all competitors
ProductCompanyStageHype Score
mRNA-1273ModernaPreclinical
0
mRNA-1273ModernaPhase 1
0
mRNA-1283ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1273.214ModernaPhase 2
0
SPIKEVAXModernaPreclinical
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1083.1ModernaPhase 2
0
SPIKEVAX BivalentModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
mRNA-1273ModernaPhase 2
0
mRNA-1073ModernaPhase 2
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1273.211ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
mRNA-1083ModernaPhase 2
0